about
Natalizumab Induction and Maintenance Therapy for Crohn's DiseaseOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisAntibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesOral 5-aminosalicylic acid for induction of remission in ulcerative colitisEtrolizumab for induction of remission in ulcerative colitisMRI scoring indices for evaluation of disease activity and severity in Crohn’s diseaseEndoscopic scoring indices for evaluation of disease activity in ulcerative colitisVedolizumab for induction and maintenance of remission in Crohn’s diseaseAnti-MAdCAM antibody for induction of remission in ulcerative colitisPlacebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitisVedolizumab for induction and maintenance of remission in ulcerative colitisMethotrexate for induction of remission in refractory Crohn's diseaseHistologic scoring indices for evaluation of disease activity in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisA comparison of endoscopic and surgical treatment of strictures in patients with Crohn’s diseaseEndoscopic scoring indices for evaluation of disease activity in Crohn’s diseaseMethotrexate for induction of remission in refractory Crohn's diseaseTacrolimus (FK506) for induction of remission in refractory ulcerative colitisMethotrexate for induction of remission in refractory Crohn's diseaseCyclosporine for induction of remission in Crohn's diseaseEndoscopic scoring indices for evaluation of disease activity in Crohn’s diseasePlacebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s diseaseOptimising monitoring in the management of Crohn's disease: a physician's perspectiveDefining Disease Severity in Inflammatory Bowel Diseases: Current and Future DirectionsA controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing LevofloxacinA comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group InvestigatorsMaintenance infliximab for Crohn's disease: the ACCENT I randomised trialCombined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trialCertolizumab pegol for the treatment of Crohn's diseaseInfliximab maintenance therapy for fistulizing Crohn's diseaseOral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study GroupFontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyHealth-related quality of life during natalizumab maintenance therapy for Crohn's diseaseQuality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study GroupBudesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsInfliximab for induction and maintenance therapy for ulcerative colitisUstekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseHistologic scoring indices for evaluation of disease activity in ulcerative colitis.The safety of vedolizumab for the treatment of ulcerative colitis.
P50
Q22250890-733C4A9B-055B-40AD-80F0-0B8D08D807A3Q24185774-03F69BD3-1DF0-48E0-A44B-59469AF388A0Q24185835-5A66C25A-2763-48ED-87C2-063737D4040EQ24185876-7A20A051-9C0F-4CDA-B294-C4F2A428B6C4Q24186788-BD28A4DF-2C31-404D-8311-59948E76335CQ24186977-31105EE4-54D7-44CC-BBDD-7D5702787F60Q24187044-2270D6F1-A6FB-4A19-A2C5-83CF27C8CC01Q24187571-03453917-702B-427F-9411-17A8CED2E8F2Q24187593-522C23DE-49BA-4816-8BB7-B99BD977041EQ24187737-306E8283-34DB-43A4-B3DD-AC44B89018E1Q24194423-588A8840-402F-41A5-BAC4-D578BE448FC7Q24194453-B2E30DD1-BA3C-4550-8322-F3FF6C158419Q24194674-02BAFF97-539E-4DCC-A226-FBEB5C008A53Q24198024-FEBFEC9E-CD5A-4CF7-BE9A-FEEC8304E397Q24198786-D71A8889-CC57-4C67-BE3B-628B08D3D9E9Q24200288-D50018B5-164C-475C-A638-068A9025D45CQ24201734-B74F8853-171C-4B4B-8874-21279C8AE935Q24202436-A29E577F-5B05-4AAA-9BF2-5069F19ACB11Q24242681-D2F41DA0-1932-48DD-A232-BFD86D7B95ECQ24245655-B6C4B1B2-AB81-4E92-A94E-920D0EA63746Q24246959-207E201B-3C34-460A-8EDF-276CF23DBF8AQ26470550-704C67D3-4D7C-498B-A0DE-670B30253430Q26471222-9DBED60D-DC94-4663-B8A9-E77913DB40FFQ27007083-520DA10B-427A-45EE-936E-A74EBD29CE84Q28087314-6AD90677-CF7C-491F-97B9-3310A1EB5987Q28145205-B5E9E373-FCE2-4F70-8681-3E4CA449B605Q28145430-58A8B007-F57F-4620-9689-69B7BB49BE59Q28202504-6EE9531F-8B82-4178-B44D-2BA0CF938220Q28213579-CD13CFCD-B776-41F6-8ADB-3EDE873B5EF2Q28236746-59DE0C77-0BE4-4A31-8D67-2AA5231992CFQ28246982-24CEFC35-66A2-41F2-B6F7-02D230585357Q28247663-F13405E9-0FFD-4FBD-B653-082928C07A69Q28253174-FCBCD7B7-6B30-4E37-97B2-73514ABC44B0Q28258882-04BE0686-7007-4206-ABDE-49EFAE49B69FQ28259222-ABD6665D-0DAD-4B96-B2E3-D3D4D5CDCDF2Q28266279-B2ADD8F2-A48B-402F-9DE0-176AA62A005CQ28285876-590FEA46-3804-4BB6-9E01-540C84B671B4Q30054715-E17C4367-9BB8-43B8-A6E0-71C216E017EDQ30234366-A0C9A803-B71B-4C69-9CA5-D32C41450AEBQ30235363-63B1A8B7-CD64-4066-B87B-DD38896459E9
P50
description
Canadees onderzoeker
@nl
Canadian professor
@en
canadisk professor
@nb
ollamh Ceanadach
@ga
name
Brian G. Feagan
@ast
Brian G. Feagan
@da
Brian G. Feagan
@de
Brian G. Feagan
@en
Brian G. Feagan
@es
Brian G. Feagan
@fr
Brian G. Feagan
@ga
Brian G. Feagan
@nb
Brian G. Feagan
@nl
Brian G. Feagan
@sl
type
label
Brian G. Feagan
@ast
Brian G. Feagan
@da
Brian G. Feagan
@de
Brian G. Feagan
@en
Brian G. Feagan
@es
Brian G. Feagan
@fr
Brian G. Feagan
@ga
Brian G. Feagan
@nb
Brian G. Feagan
@nl
Brian G. Feagan
@sl
altLabel
Brian Feagan
@en
Brian Feagan
@nb
prefLabel
Brian G. Feagan
@ast
Brian G. Feagan
@da
Brian G. Feagan
@de
Brian G. Feagan
@en
Brian G. Feagan
@es
Brian G. Feagan
@fr
Brian G. Feagan
@ga
Brian G. Feagan
@nb
Brian G. Feagan
@nl
Brian G. Feagan
@sl
P106
P21
P214
198153895169902410000
P27
P31
P496
0000-0002-6914-3822
P735
P7859
viaf-198153895169902410000